AU2001285143A1 - Methods and compositions for targeted delivery - Google Patents

Methods and compositions for targeted delivery

Info

Publication number
AU2001285143A1
AU2001285143A1 AU2001285143A AU8514301A AU2001285143A1 AU 2001285143 A1 AU2001285143 A1 AU 2001285143A1 AU 2001285143 A AU2001285143 A AU 2001285143A AU 8514301 A AU8514301 A AU 8514301A AU 2001285143 A1 AU2001285143 A1 AU 2001285143A1
Authority
AU
Australia
Prior art keywords
compositions
methods
targeted delivery
targeted
delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001285143A
Inventor
David S. Scher
Mark A Tracy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alkermes Controlled Therapeutics Inc
Original Assignee
Alkermes Inc
Alkermes Controlled Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Inc, Alkermes Controlled Therapeutics Inc filed Critical Alkermes Inc
Publication of AU2001285143A1 publication Critical patent/AU2001285143A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2001285143A 2000-08-23 2001-08-21 Methods and compositions for targeted delivery Abandoned AU2001285143A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/644,631 2000-08-23
US09/644,631 US6565888B1 (en) 2000-08-23 2000-08-23 Methods and compositions for the targeted delivery of biologically active agents
PCT/US2001/026094 WO2002015877A2 (en) 2000-08-23 2001-08-21 Methods and compositions for targeted delivery

Publications (1)

Publication Number Publication Date
AU2001285143A1 true AU2001285143A1 (en) 2002-03-04

Family

ID=24585726

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001285143A Abandoned AU2001285143A1 (en) 2000-08-23 2001-08-21 Methods and compositions for targeted delivery

Country Status (3)

Country Link
US (2) US6565888B1 (en)
AU (1) AU2001285143A1 (en)
WO (1) WO2002015877A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001240020B9 (en) * 2000-03-01 2008-12-04 Medimmune, Llc High potency recombinant antibodies and method for producing them
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
ATE474854T1 (en) * 2000-01-27 2010-08-15 Medimmune Llc RSV NEUTRALIZING ANTIBODIES WITH VERY HIGH AFFINITY
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
KR20050044523A (en) * 2001-11-19 2005-05-12 벡톤 디킨슨 앤드 컴퍼니 Pharmaceutical compositions in particulate form
WO2003059321A1 (en) 2001-12-21 2003-07-24 Soane David S Use of oligomers and polymers for drug solublization, stabilization, and delivery
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
NZ540282A (en) 2002-11-18 2008-06-30 Yaupon Therapeutics Inc Analgesic uses of norketamine and ketamine/norketamine prodrugs
GB0300881D0 (en) * 2003-01-15 2003-02-12 Secr Defence Therapeutic treatment
WO2005058474A1 (en) * 2003-12-19 2005-06-30 Alk-Abelló A/S Cryogranulation and storage method for active pharmaceutical agents
WO2006035417A2 (en) * 2004-09-27 2006-04-06 Sigmoid Biotechnologies Limited Dihydropyrimidine microcapsule - formulations
CA2585891A1 (en) * 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
WO2006078841A1 (en) * 2005-01-21 2006-07-27 President And Fellows Of Harvard College Systems and methods for forming fluidic droplets encapsulated in particles such as colloidal particles
TWI398272B (en) * 2005-03-08 2013-06-11 Intervet Int Bv Chemically defined stabiliser
US9051379B2 (en) 2005-07-07 2015-06-09 Fulcrum Sp Ltd. Sp1 polypeptides, modified Sp1 polypeptides and uses thereof
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
EP2101834B1 (en) * 2006-12-01 2015-03-25 Wake Forest University Health Sciences Medical devices incorporating collagen inhibitors
GB2446780A (en) * 2007-02-22 2008-08-27 Glide Pharmaceutical Technolog An elongate parenteral injection body having an injection point of angle 10 to 40 degrees.
US20080260725A1 (en) * 2007-03-29 2008-10-23 Ulhas Naik Tag and target delivery system
AU2008236622B2 (en) 2007-04-09 2013-01-10 Wake Forest University Health Sciences Oxygen-generating compositions for enhancing cell and tissue survival in vivo
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US20090061009A1 (en) * 2007-08-29 2009-03-05 Joseph Schwarz Composition and Method of Treatment of Bacterial Infections
GB0721081D0 (en) 2007-10-26 2007-12-05 Metcalfe Susan M Immuno-modulatory composition
US8691274B2 (en) 2008-02-14 2014-04-08 Wake Forest University Health Sciences Inkjet printing of tissues and cells
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
US20100189800A1 (en) * 2009-01-23 2010-07-29 Peter Markland Continous double emulsion process for making microparticles
CN102470106B (en) 2009-05-18 2015-09-23 希格默伊德药业有限公司 Comprise the compositions of oil droplet
IN2012DN00781A (en) * 2009-08-12 2015-06-26 Sigmoid Pharma Ltd
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
CA2921491C (en) 2012-08-23 2022-06-21 Susan Marie Metcalfe Neurotherapeutic nanoparticle compositions and devices
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
EP3079668A1 (en) 2013-12-09 2016-10-19 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
ES2858517T3 (en) 2014-11-07 2021-09-30 Sublimity Therapeutics Ltd Compositions comprising cyclosporin
WO2017019214A1 (en) 2015-07-29 2017-02-02 Musc Foundation For Research Development Donor organ pre-treatment formulation
JP2018532785A (en) 2015-11-06 2018-11-08 フラウンホファー ゲセルシャフト ツール フェールデルンク ダー アンゲヴァンテン フォルシュンク エー．ファオ． Compositions comprising biocompatible and biodegradable polymers, nanocarriers and drugs and methods for making and using the same
IL243838A (en) 2016-01-28 2017-07-31 Sp Nano Ltd Composition comprising sp1 and carbon based nanoparticles and uses thereof
IL243839B (en) 2016-01-28 2018-01-31 Sp Nano Ltd Conductive yarn

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4919929A (en) 1984-02-01 1990-04-24 Stolle Research & Development Corporation Mammal immunization
EP0545913B1 (en) 1986-08-18 1999-02-24 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5019400A (en) 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
ES2062530T3 (en) 1989-05-01 1994-12-16 Alkermes Inc PROCEDURE FOR PRODUCING SMALL PARTICLES OF BIOLOGICALLY ACTIVE MOLECULES.
US5330768A (en) 1991-07-05 1994-07-19 Massachusetts Institute Of Technology Controlled drug delivery using polymer/pluronic blends
AU4932493A (en) 1992-09-25 1994-04-26 Dynagen, Inc. An immunobooster for delayed release of immunogen
EP0595030A3 (en) 1992-10-01 1995-06-07 Tanabe Seiyaku Co Sustained release multi-core microsphere preparation and method for producing the same.
JPH09504027A (en) 1993-10-22 1997-04-22 ジェネンテク，インコーポレイテッド Methods and compositions for microencapsulation of antigens for use as vaccines
FR2718642B1 (en) 1994-04-15 1996-07-12 Pf Medicament Biodegradable controlled release microspheres and their preparation process.
GB9412273D0 (en) * 1994-06-18 1994-08-10 Univ Nottingham Administration means
IE75744B1 (en) * 1995-04-03 1997-09-24 Elan Corp Plc Controlled release biodegradable micro- and nanospheres containing cyclosporin
US6015576A (en) 1997-08-29 2000-01-18 Bio-Sphere Technology, Inc. Method for inducing a systemic immune response to an antigen
US5817343A (en) 1996-05-14 1998-10-06 Alkermes, Inc. Method for fabricating polymer-based controlled-release devices
US5840322A (en) 1996-12-19 1998-11-24 Ramot-University Authority For Applied Research & Industrial Devel. Ltd. Anti-oral-microbial adhesion fraction derived from vaccinium
US6020004A (en) * 1997-04-17 2000-02-01 Amgen Inc. Biodegradable microparticles for the sustained delivery of therapeutic drugs
US6113947A (en) * 1997-06-13 2000-09-05 Genentech, Inc. Controlled release microencapsulated NGF formulation
US6444223B1 (en) 1999-05-28 2002-09-03 Alkermes Controlled Therapeutics, Inc. Method of producing submicron particles of a labile agent and use thereof
US6465425B1 (en) 2000-02-10 2002-10-15 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins

Also Published As

Publication number Publication date
WO2002015877A8 (en) 2002-11-21
WO2002015877A2 (en) 2002-02-28
WO2002015877A3 (en) 2003-02-27
US7097857B2 (en) 2006-08-29
US6565888B1 (en) 2003-05-20
US20060141041A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
AU2001285143A1 (en) Methods and compositions for targeted delivery
AU2778801A (en) Antisense compositions and methods
AU2002357119A1 (en) Mitocidal compositions and methods
IL144325A0 (en) Compositions and methods for mucosal delivery
AU2001294814A1 (en) Pumpcn compositions and uses thereof
AU2001261566A1 (en) Well service composition and method
AU2001280968A1 (en) Compositions and methods for directed gene assembly
AU2001294808A1 (en) Catecholamine pharmaceutical compositions and methods
AU2001253255A1 (en) Compositions and methods for inhibiting gene expression
AU2001280604A1 (en) Compositions comprising icariside i and anhydroicaritin and methods for making the same
AU2001286651A1 (en) Microparticle composition and method
AU2001245987A1 (en) Compositions and methods for gene therapy
AU2001238485A1 (en) Methods and compositions for gene delivery
AU2002357748A1 (en) Osteopontin-related compositions and methods
AU2001233932A1 (en) Method and composition
AU6094200A (en) Nor gene compositions and methods for use thereof
AU2002308649A1 (en) Compositions and methods for enhancing drug delivery
AU2001233086A1 (en) Ceramidase compositions and methods based thereon
AU2002366809A1 (en) Syn3 compositions and methods
EP1173192A4 (en) Methods and compositions for targeted drug delivery
EP1411897A4 (en) Compositions and methods for intracellular delivery
AU3926000A (en) Methods and compositions for drug delivery
AU2001261317A1 (en) Immunostimulant compositions and associated methods
AU2002239775A1 (en) Chemical-library composition and method
AU2002350181A1 (en) Compositions and methods for viral delivery